Posted by Michael Wonder on 31 Aug 2020
A new biosimilar to NovoRapid is included in the high-cost protection
28 August 2020 - Insulin aspart Sanofi (insulin aspart) solution for injection for the treatment of diabetes is included in the high-cost protection from 28 August 2020.
Insulin aspart Sanofi is a biosimilar to the reference medicine NovoRapid and, like NovoRapid, Insulin aspart Sanofi contains the active substance insulin aspart which is a fast-acting insulin.
The prices for the packaging of Insulin aspart Sanofi are lower than the prices for the corresponding packaging of NovoRapid.
